Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism Academic Article uri icon


MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Hypothyroidism
  • Immunologic Factors
  • Lymphoma, Large B-Cell, Diffuse
  • Thalidomide
  • Tumor Necrosis Factor-alpha


  • As the use of lenalidomide expands, the poorly understood phenomenon of lenalidomide-induced thyroid abnormalities will increase. In this study, we compared rates of therapy-induced hypothyroidism in 329 patients with diffuse large B-cell lymphoma (DLBCL) treated with conventional chemotherapy (DLBCL-c) or conventional chemotherapy plus lenalidomide (DLBCL-len). We measured serum levels of tumor necrosis factor α, interferon gamma, interleukin 6, interleukin 12, and interleukin 15 before and after treatment. We found a significantly higher rate of therapy-induced hypothyroidism in the DLBCL-len group (25.8% vs. 1.3%), and we found a statistically significant increase in serum tumor necrosis factor α in patients with lenalidomide-induced hypothyroidism.

publication date

  • January 2015



  • Academic Article



  • eng

PubMed Central ID

  • PMC5002942

Digital Object Identifier (DOI)

  • 10.1016/j.exphem.2014.10.009

PubMed ID

  • 25448491

Additional Document Info

start page

  • 74

end page

  • 8


  • 43


  • 2